Lancet Respiratory Medicine

Papers
(The H4-Index of Lancet Respiratory Medicine is 95. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Postoperative CPAP after major abdominal surgery731
Time to move away from an oxygen-centric model of pulmonary infarction?554
Why has the incidence of tuberculosis not reduced in London during the COVID-19 pandemic?546
Concerns regarding a suggested long COVID paradigm – Authors' reply467
The burden of tuberculosis in Libya414
European Respiratory Society International Congress 2022400
Video laryngoscopy is not the nemesis of direct laryngoscopy373
Major gaps in childhood pneumonia research priorities remain366
The course of action for effective anti-cytokine treatment in COVID-19351
Correction to Lancet Respir Med 2024; 12: 129–40303
Correction to Lancet Respir Med 2019; 7: 745–56295
Rituximab for connective tissue disease-associated interstitial lung disease288
Savolitinib in NSCLC: progress in the MET exon 14 journey269
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress268
Chronic obstructive pulmonary disease: 10 years of precision-guided success262
Broad protection from SARS-CoV-2 variants without antigen matching254
Concerns about PRISm239
GOLD report: 2022 update222
Thoracentesis: an old story and some new sources219
US Senate committee investigates asthma inhaler prices206
Eat or heat: fuel poverty and childhood respiratory health204
Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement202
Advancing precision medicine for acute respiratory distress syndrome199
Interstitial lung disease: a decade of progress and hope188
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials188
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study187
FLiRTing with danger as SARS-CoV-2 variants evolve186
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis185
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis179
Long COVID: systemic inflammation and obesity as therapeutic targets175
Opioids bring peace to patients with IPF cough174
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study168
Australia bans engineered stone to prevent silicosis167
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership159
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial158
Genetic associations and lung function in IPF: unexpected answers, persistent questions157
Improving lifelong respiratory health after preterm birth153
Cytokine adsorption and ECMO in patients with COVID-19151
Sarcoidosis and fatigue: there is a useful cognitive treatment? – Authors' reply151
Claudio Castanos—leader in cystic fibrosis care in Argentina149
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials143
Priorities for NICE in health and social care142
US EPA signals renewed regulatory scrutiny of toxic air pollution141
Solid and semi-solid perspectives in thoracic surgery140
Nasally delivered SARS-CoV-2 vaccines: future promise and challenges138
Awake prone positioning in COVID-19: is tummy time ready for prime time?137
Overcoming barriers to scaling up tuberculosis preventive treatment for household contacts136
Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials136
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial135
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis135
Nintedanib for treating progressive fibrosing interstitial lung diseases133
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study132
Association of SARS-CoV-2 infection and persistence with long COVID129
Misdiagnosis of sarcoidosis128
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial128
Extracorporeal cardiopulmonary resuscitation: not why, but how128
Correction to Lancet Respir Med 2021; 9: 1275–87126
Correction to Lancet Respir Med 2022; 10: 972–84126
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis125
Vaccination in the world's top athletes122
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co119
Correction to Lancet Respir Med 2025; 13: 244–55119
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing s119
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis117
Chronic cough as a disease: implications for practice, research, and health care116
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO115
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial115
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta115
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub114
Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial113
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial113
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial111
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study111
Venus and Mars: chest wall deformity and thoracic disease107
Trouble with promoting lung cancer screening in never-smokers107
COPD: a complex, multifactorial, but preventable disease?106
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO106
NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma106
Underappreciated causes of obstructive lung disease105
Correction to Lancet Respir Med 2023; 11: 1064–74102
Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial101
Spirometry in female individuals – Authors' reply101
COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion100
Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis100
Prevalence of sleep-disordered breathing in an African general population: The Benin Society and Sleep (BeSAS) study100
Unavailability of varenicline: a global tragedy for the fight against the tobacco epidemic100
Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven ot100
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials98
COP27 Climate Change Conference: urgent action needed for Africa and the world97
Realignment of clinical research after the COVID-19 era96
Inhaled budesonide for early treatment of COVID-1996
Liberal or restrictive transfusion for VV ECMO96
Young person with long COVID after mild disease96
Developments and priorities in bronchiectasis research96
Opioid use and sleep apnoea95
0.16841697692871